Dividend Payout Ratio: 39.88%
Is the dividend payout ratio high or low?
The dividend payout ratio of 39.88% is 29% below its 5-year average of 56.52%, near the low end of its 5-year range (15.69%–102.61%).
As of Saturday, June 27, 2026. 27.65% below its 12-month average of 55.12%.
Dividend Payout Ratio (39.88%) = TTM Dividends/Share ($1.80) / TTM EPS ($4.52)
GSK Dividend Payout Ratio (TTM) Chart
GSK Average Dividend Payout Ratio Chart
GSK Current vs Average Dividend Payout Ratio Chart
GSK Dividend Payout Ratio Metrics
DIVIDEND PAYOUT RATIO
39.88%
DIVIDEND PAYOUT RATIO AVG TTM
55.12%
DIVIDEND PAYOUT RATIO AVG 3Y
57.90%
DIVIDEND PAYOUT RATIO AVG 5Y
56.52%
DIVIDEND PAYOUT RATIO AVG 10Y
68.71%
DIVIDEND PAYOUT RATIO AVG 15Y
61.28%
DIVIDEND PAYOUT RATIO AVG 20Y
57.60%
CURRENT VS TTM AVG
-27.65%
CURRENT VS 3Y AVG
-31.12%
CURRENT VS 5Y AVG
-29.45%
CURRENT VS 10Y AVG
-41.96%
CURRENT VS 15Y AVG
-34.93%
CURRENT VS 20Y AVG
-30.76%
Annual Payout Ratio History
| Year | EPS | Dividend | Payout Ratio |
|---|---|---|---|
| 2025 | $7.59 | $1.70 | 22.4% |
| 2024 | $1.58 | $1.56 | 98.8% |
| 2023 | $3.10 | $1.39 | 44.8% |
| 2022 | $8.99 | $1.68 | 18.7% |
| 2021 | $3.71 | $2.32 | 62.6% |
| 2020 | $3.93 | $2.06 | 52.3% |
| 2019 | $3.10 | $2.06 | 66.4% |
| 2018 | $2.34 | $2.16 | 92.2% |
| 2017 | $1.05 | $2.06 | 195.9% |
| 2016 | $0.59 | $2.77 | 467.9% |
| 2015 | $6.42 | $2.45 | 38.1% |
| 2014 | $2.24 | $2.65 | 118.2% |
| 2013 | $4.67 | $2.41 | 51.5% |
| 2012 | $3.74 | $2.48 | 66.2% |
| 2011 | $4.07 | $2.21 | 54.1% |
| 2010 | $1.25 | $2.00 | 160.1% |
| 2009 | $4.40 | $1.85 | 42.2% |
| 2008 | $3.23 | $2.14 | 66.3% |
| 2007 | $4.68 | $2.06 | 44.0% |
| 2006 | $4.66 | $1.74 | 37.3% |
| 2005 | $3.54 | $1.53 | 43.1% |
| 2004 | $3.26 | $1.62 | 49.7% |
| 2003 | $3.46 | $1.38 | 39.8% |
| 2002 | $2.67 | $1.89 | 70.7% |
| 2001 | $1.83 | $0.85 | 46.6% |
| 2000 | $2.54 | $2.03 | 79.9% |
| 1999 | $2.03 | $1.13 | 55.7% |
| 1998 | $2.13 | $1.15 | 53.9% |
| 1997 | $2.15 | $1.22 | 56.7% |
| 1996 | $2.43 | $1.06 | 43.5% |
Dividend Payout Ratio Formula & Definition
The payout ratio shows the share of trailing-12-month earnings paid out as dividends. Lower leaves more room to grow the dividend; a ratio persistently above 100% means dividends exceed earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Dividend Payout Ratio FAQ
- What is the dividend payout ratio for GSK plc (GSK)?
- The dividend payout ratio for GSK stock is 39.88%.
- Is GSK plc's dividend payout ratio high or low?
- The dividend payout ratio of 39.88% is 29% below its 5-year average of 56.52%, near the low end of its 5-year range (15.69%–102.61%).
- What is the TTM average dividend payout ratio for GSK plc (GSK)?
- The TTM average dividend payout ratio for GSK stock is 55.12%.
- What is the 3Y average dividend payout ratio for GSK plc (GSK)?
- The 3Y average dividend payout ratio for GSK stock is 57.90%.
- What is the 5Y average dividend payout ratio for GSK plc (GSK)?
- The 5Y average dividend payout ratio for GSK stock is 56.52%.
- What is the 10Y average dividend payout ratio for GSK plc (GSK)?
- The 10Y average dividend payout ratio for GSK stock is 68.71%.
- What is the 15Y average dividend payout ratio for GSK plc (GSK)?
- The 15Y average dividend payout ratio for GSK stock is 61.28%.
- What is the 20Y average dividend payout ratio for GSK plc (GSK)?
- The 20Y average dividend payout ratio for GSK stock is 57.60%.
GSK Dividend Payout Ratio History
| DATE | DIVIDEND PAYOUT RATIO |
|---|---|
| 2026-06-26 | 39.88% |
| 2026-06-24 | 39.89% |
| 2026-06-22 | 39.88% |
| 2026-06-17 | 39.87% |
| 2026-06-15 | 39.88% |
| 2026-06-11 | 39.88% |
| 2026-06-09 | 39.87% |
| 2026-06-05 | 39.87% |
| 2026-06-03 | 39.86% |
| 2026-06-01 | 39.86% |
| 2026-05-28 | 39.87% |
| 2026-05-26 | 39.88% |
| 2026-05-21 | 39.86% |
| 2026-05-19 | 39.88% |
| 2026-05-15 | 49.49% |
| 2026-05-13 | 39.28% |
| 2026-05-11 | 39.28% |
| 2026-05-07 | 39.31% |
| 2026-05-05 | 39.29% |
| 2026-05-01 | 39.29% |
| 2026-04-29 | 39.27% |
| 2026-04-27 | 40.44% |
| 2026-04-23 | 40.44% |
| 2026-04-21 | 40.43% |
| 2026-04-17 | 40.44% |
| 2026-04-15 | 40.45% |
| 2026-04-13 | 40.46% |
| 2026-04-09 | 40.46% |
| 2026-04-07 | 40.44% |
| 2026-04-02 | 40.43% |
| 2026-03-31 | 40.44% |
| 2026-03-27 | 40.46% |
| 2026-03-25 | 40.44% |
| 2026-03-23 | 40.43% |
| 2026-03-19 | 40.45% |
| 2026-03-17 | 40.46% |
| 2026-03-13 | 40.44% |
| 2026-03-11 | 40.43% |
| 2026-03-09 | 40.46% |
| 2026-03-05 | 40.44% |
| 2026-03-03 | 40.44% |
| 2026-02-27 | 40.45% |
| 2026-02-25 | 40.44% |
| 2026-02-23 | 40.45% |
| 2026-02-19 | 38.69% |
| 2026-02-17 | 38.70% |
| 2026-02-12 | 38.70% |
| 2026-02-10 | 38.69% |
| 2026-02-06 | 38.69% |
| 2026-02-04 | 38.70% |
| 2026-02-02 | 48.04% |
| 2026-01-29 | 48.01% |
| 2026-01-27 | 48.01% |
| 2026-01-23 | 48.03% |
| 2026-01-21 | 48.02% |
| 2026-01-16 | 48.05% |
| 2026-01-14 | 48.02% |
| 2026-01-12 | 48.03% |
| 2026-01-08 | 48.03% |
| 2026-01-06 | 48.04% |
| 2026-01-02 | 48.01% |
| 2025-12-30 | 48.03% |
| 2025-12-26 | 48.03% |
| 2025-12-23 | 48.02% |
| 2025-12-19 | 48.04% |
| 2025-12-17 | 48.02% |
| 2025-12-15 | 48.02% |
| 2025-12-11 | 48.02% |
| 2025-12-09 | 48.04% |
| 2025-12-05 | 48.03% |
| 2025-12-03 | 48.04% |
| 2025-12-01 | 48.01% |
| 2025-11-26 | 48.03% |
| 2025-11-24 | 48.04% |
| 2025-11-20 | 48.03% |
| 2025-11-18 | 48.01% |
| 2025-11-14 | 59.02% |
| 2025-11-12 | 46.77% |
| 2025-11-10 | 46.78% |
| 2025-11-06 | 46.79% |
| 2025-11-04 | 46.78% |
| 2025-10-31 | 46.78% |
| 2025-10-29 | 46.79% |
| 2025-10-27 | 75.85% |
| 2025-10-23 | 75.86% |
| 2025-10-21 | 75.83% |
| 2025-10-17 | 75.85% |
| 2025-10-15 | 75.84% |
| 2025-10-13 | 75.85% |
| 2025-10-09 | 75.83% |
| 2025-10-07 | 75.84% |
| 2025-10-03 | 75.83% |
| 2025-10-01 | 75.83% |
| 2025-09-29 | 75.84% |
| 2025-09-25 | 75.86% |
| 2025-09-23 | 75.82% |
| 2025-09-19 | 75.83% |
| 2025-09-17 | 75.83% |
| 2025-09-15 | 75.82% |
| 2025-09-11 | 75.82% |
| 2025-09-09 | 75.82% |
| 2025-09-05 | 75.86% |
| 2025-09-03 | 75.83% |
| 2025-08-29 | 75.82% |
| 2025-08-27 | 75.82% |
| 2025-08-25 | 75.83% |
| 2025-08-21 | 75.83% |
| 2025-08-19 | 75.83% |
| 2025-08-15 | 93.50% |
| 2025-08-13 | 73.82% |
| 2025-08-11 | 73.82% |
| 2025-08-07 | 73.82% |
| 2025-08-05 | 73.82% |
| 2025-08-01 | 73.82% |
| 2025-07-30 | 73.79% |
| 2025-07-28 | 83.50% |
| 2025-07-24 | 83.52% |
| 2025-07-22 | 83.51% |
| 2025-07-18 | 83.50% |
| 2025-07-16 | 83.49% |
| 2025-07-14 | 83.51% |
| 2025-07-10 | 83.52% |
| 2025-07-08 | 83.52% |
| 2025-07-03 | 83.50% |
| 2025-07-01 | 83.50% |
| 2025-06-27 | 83.51% |
| 2025-06-25 | 83.49% |
| 2025-06-23 | 83.49% |
| 2025-06-18 | 83.51% |
| 2025-06-16 | 83.51% |
| 2025-06-12 | 83.52% |
| 2025-06-10 | 83.51% |
| 2025-06-06 | 83.52% |
| 2025-06-04 | 83.51% |
| 2025-06-02 | 83.52% |
| 2025-05-29 | 83.49% |
| 2025-05-27 | 83.49% |
| 2025-05-22 | 83.49% |
| 2025-05-20 | 83.48% |
| 2025-05-16 | 83.50% |
| 2025-05-14 | 80.45% |
| 2025-05-12 | 80.46% |
| 2025-05-08 | 80.46% |
| 2025-05-06 | 80.47% |
| 2025-05-02 | 80.46% |
| 2025-04-30 | 80.48% |
| 2025-04-28 | 100.00% |
| 2025-04-24 | 100.00% |
| 2025-04-22 | 100.01% |
| 2025-04-17 | 100.01% |
| 2025-04-15 | 100.02% |
| 2025-04-11 | 100.02% |
| 2025-04-09 | 99.99% |
| 2025-04-07 | 99.98% |
| 2025-04-03 | 99.99% |
| 2025-04-01 | 100.01% |
| 2025-03-28 | 100.01% |
| 2025-03-26 | 99.99% |
| 2025-03-24 | 100.00% |
| 2025-03-20 | 100.00% |
| 2025-03-18 | 99.99% |
| 2025-03-14 | 99.99% |
| 2025-03-12 | 100.01% |
| 2025-03-10 | 100.01% |
| 2025-03-06 | 100.00% |
| 2025-03-04 | 100.01% |
| 2025-02-28 | 100.01% |
| 2025-02-26 | 99.98% |
| 2025-02-24 | 100.01% |
| 2025-02-20 | 100.34% |
| 2025-02-18 | 100.32% |
| 2025-02-13 | 100.36% |
| 2025-02-11 | 100.36% |
| 2025-02-07 | 100.36% |
| 2025-02-05 | 100.36% |
| 2025-02-03 | 102.61% |
| 2025-01-30 | 102.59% |
| 2025-01-28 | 102.60% |
| 2025-01-24 | 102.59% |
| 2025-01-22 | 102.60% |
| 2025-01-17 | 102.60% |
| 2025-01-15 | 102.58% |
| 2025-01-13 | 102.61% |
| 2025-01-08 | 102.60% |
| 2025-01-06 | 102.61% |
| 2025-01-02 | 102.59% |
| 2024-12-30 | 102.58% |
| 2024-12-26 | 102.58% |
| 2024-12-23 | 102.58% |
| 2024-12-19 | 102.60% |
| 2024-12-17 | 102.57% |
| 2024-12-13 | 102.59% |
| 2024-12-11 | 102.59% |
| 2024-12-09 | 102.57% |
| 2024-12-05 | 102.58% |
| 2024-12-03 | 102.61% |
| 2024-11-29 | 102.60% |
| 2024-11-26 | 102.61% |
| 2024-11-22 | 102.61% |
| 2024-11-20 | 102.57% |
| 2024-11-18 | 102.60% |
| 2024-11-14 | 99.34% |
| 2024-11-12 | 99.32% |
| 2024-11-08 | 99.34% |
| 2024-11-06 | 99.32% |
| 2024-11-04 | 99.34% |
| 2024-10-31 | 99.34% |
| 2024-10-29 | 61.94% |
| 2024-10-25 | 61.96% |
| 2024-10-23 | 61.97% |
| 2024-10-21 | 61.95% |
| 2024-10-17 | 61.96% |
| 2024-10-15 | 61.96% |
| 2024-10-11 | 61.97% |
| 2024-10-09 | 61.93% |
| 2024-10-07 | 61.94% |
| 2024-10-03 | 61.97% |
| 2024-10-01 | 61.95% |
| 2024-09-27 | 61.96% |
| 2024-09-25 | 61.97% |
| 2024-09-23 | 61.95% |
| 2024-09-19 | 61.95% |
| 2024-09-17 | 61.96% |
| 2024-09-13 | 61.94% |
| 2024-09-11 | 61.97% |
| 2024-09-09 | 61.97% |
| 2024-09-05 | 61.94% |
| 2024-09-03 | 61.95% |
| 2024-08-29 | 61.94% |
| 2024-08-27 | 61.95% |
| 2024-08-23 | 61.96% |
| 2024-08-21 | 61.97% |
| 2024-08-19 | 61.95% |
| 2024-08-15 | 60.94% |
| 2024-08-13 | 60.95% |
| 2024-08-09 | 60.94% |
| 2024-08-07 | 60.96% |
| 2024-08-05 | 60.94% |
| 2024-08-01 | 60.96% |
| 2024-07-30 | 54.12% |
| 2024-07-26 | 54.11% |
| 2024-07-24 | 54.12% |
| 2024-07-22 | 54.11% |
| 2024-07-18 | 54.12% |
| 2024-07-16 | 54.11% |
| 2024-07-12 | 54.13% |
| 2024-07-10 | 54.12% |
| 2024-07-08 | 54.11% |
| 2024-07-03 | 54.11% |
| 2024-07-01 | 54.11% |
| 2024-06-27 | 54.13% |
| 2024-06-25 | 54.13% |
| 2024-06-21 | 54.12% |
| 2024-06-18 | 54.12% |
| 2024-06-14 | 54.11% |
| 2024-06-12 | 54.12% |
| 2024-06-10 | 54.10% |
| 2024-06-06 | 54.10% |
| 2024-06-04 | 54.09% |
| 2024-05-31 | 54.10% |
Showing the most recent 260 of 2,448 data points. The chart above shows the full history.
About GSK plc
GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat illnesses by producing both vaccines and a comprehensive range of specialty and general medicines for markets across the United Kingdom, the United States, and internationally. The company's operations are organized into two key divisions: Commercial Operations and Total R&D. Its extensive vaccine portfolio includes immunizations against shingles, meningitis, respiratory syncytial virus (RSV), seasonal and pandemic influenza, and polio. Beyond preventative care, GSK provides diverse therapeutic products covering critical areas such as HIV, oncology, respiratory and immunology conditions, and other specialized medical fields. This also encompasses inhaled treatments for chronic respiratory ailments like asthma and chronic obstructive pulmonary disease (COPD), along with antibiotics for various infections. Innovation at GSK is frequently driven by strategic partnerships. Notable collaborations include an agreement with CureVac to advance mRNA-based influenza vaccines, and alliances with Wave Life Sciences and Elsie Biotechnologies focused on developing oligonucleotide platforms. Furthermore, GSK has established two distinct strategic collaborations with Relation to progress therapeutics for fibrotic diseases and osteoarthritis. The company is also engaged in a multi-target strategic alliance aimed at developing pioneering treatments for individuals suffering from Parkinson's disease, and a partnership with Flagship Pioneering to identify novel medicines and vaccines.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Luke Victor Miels